- Analysts
- Dividend Payments
- Government Awards
- Insiders
- Lobbying Expenses
- Segment Revenues
- Shareholder Structure
- Supply / Portfolio
- Valuation Models [Soon]
- Board & Officers
- Business Intelligence
- Employee Voice
- ESG Scores [Soon]
- Mergers and Acquisitions
- Qualified Risks
- Clinical Trials [Soon]
- H1B/PERM Strategy
- Industry H&T [Soon]
- Macro
- News
- Patents / Trademarks [Soon]
- Peer Performance
- Relevant Disputes [Soon]
Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for …
Shareholders
Major Shareholders · StructureBreakdown
The breakdown presents the total weighting of the relevant parties: Institutes, Insiders & Public. for Unicycive Therapeutics, Inc.
Beneficial Owners Beta
Beneficial owners who control a significant portion of the shares outstanding.
| Owner | Shares | Equivalence - $0.67 per share | Last Form/Filing | Last Transaction |
|---|---|---|---|---|
| 10% Holder | ||||
| - No data - | ||||
| Officers/Directors Below 10% | ||||
| - No data - | ||||
Shareholder Breakdown
The breakdown presents the total weighting of the relevant parties: Institutes, Insiders & Public.
It's perfect to get a quick briefing regarding the shareholder structure of Unicycive Therapeutics, Inc.
Short
We source Fail-To-Deliver data every month, directly from the SEC.